

## **Meeting Minutes: Drug Formulary Committee - DRAFT**

Date and Time: April 17, 2024; 9:15 a.m. – 1:30 p.m. (Central Time)

Minutes prepared by: Naana Osei-Boateng and Dave Hoang

Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building,

Room 2370

#### **Attendance**

- Members in attendance: Stuart Williams, JD; Jacques Beasley; Arthur Beisang, MD; Margaret Artz, RPh,
  PhD; Emily Jaeger, PharmD; Kathryn Lombardo, MD; Katherine Montag Schafer, PharmD; Kelly Ruby,
  PharmD; Sheila Scheuer, PharmD; Sofia Shrestha, PharmD; Sandra Widhalm Murphy, RPh; Jena Wirt,
  DO; Julie Wolfgram, DNP, FNP
- Members absent: Mary Mescher Benbenek, PhD, APRN; Monica Brands, RPh; Amirala Pasha, DO, JD;
   James Phillips, MD
- <u>DHS staff present</u>: Dave Hoang, PharmD, MBA; Chad Hope, PharmD; Nathan Chomilo, MD; Aaron Drake, RPh.
- Others in attendance: Julie McKee, PharmD; Chloe Groomes, PharmD; Naana Osei-Boateng, PharmD

# **Report of the Chair**

Stuart Williams presided over the meeting.

#### **Approval of Minutes**

 The committee reviewed and accepted the Minutes from the December 2023 meeting with the following changes:

Correction of the spelling of the name of DFC member Katherine Montag Schafer, PharmD

#### **DHS Housekeeping**

- New DHS staff member Aaron Drake was introduced to the DFC.
- Chad Hope also announced the expansion of Magellan services with the implementation of a new pharmacy point of sale system scheduled for October 2024.

### **Old Business**

None

## **Uniform PDL Management Guidance**

The DFC unanimously voted to approve the Uniform PDL Management Guidance draft presented and reviewed by DHS with the following amendment:

• When a drug listed on the Uniform PDL is discontinued by the manufacturer, the following steps are recommended:

## **Specialty Drugs for Continued Prior Authorization (PA)**

- The committee discussed Leqembi and recommended to DHS by a unanimous vote that Leqembi remain
  on PA with the proposed criteria and that the drug be re-reviewed at the first DFC meeting 9 months
  from today's meeting.
- The committee discussed Vowst and recommended to DHS by a unanimous vote that Vowst remain on PA with the proposed criteria.
- The committee discussed Rebyota and recommended to DHS by a unanimous vote that Rebyota remain on PA with the proposed criteria.
- The committee discussed Veozah and recommended to DHS by a unanimous vote that Veozah remain on PA with the proposed criteria.
- The committee discussed Rystiggo and recommended to DHS by a unanimous vote that Rystiggo remain on PA with the proposed criteria.
- The committee discussed Hemady and recommended to DHS by a majority vote that Hemady remain on PA with the proposed criteria.
- The committee discussed Zurzuvae and recommended to DHS by a unanimous vote that Zurzuvae remain on PA with the proposed criteria.
- The committee discussed Elevidys and recommended to DHS by a unanimous vote that Elevidys remain on PA with the following amendments to the proposed criteria.
  - Amendment of bullet # 8 to read: Patient has not received a DMD-directed antisense oligonucleotide within the past 30-7 days; AND
  - Amendment of bullet # 14 to read: Approval is for one time administration and may not be renewed

- Authorization will be for up to 14-60 days from approval or until the day before the patient's 6th birthday, whichever comes first
- The committee discussed Vevye and recommended to DHS by a unanimous vote that Vevye remain on PA with the proposed criteria.
- The committee discussed Voquezna, Voquezna Dual Pak, Voquezna Triple Pak and recommended to DHS by a unanimous vote that the aforementioned products remain on PA with the proposed criteria.

# **Preferred Drug List (PDL) Review**

- The committee discussed the Acne Agents, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  - ALTRENO (TOPICAL), ARAZLO (TOPICAL), CABTREO (TOPICAL), CLINDAMYCIN / BENZOYL
    PEROXIDE (ACANYA) W/PUMP (TOPICAL), CLINDAMYCIN / BENZOYL PEROXIDE (ONEXTON)
    W/PUMP (TOPICAL), TAZAROTENE FOAM (TOPICAL), TAZAROTENE GEL (TOPICAL) and
    TRETINOIN MICROSPHERES GEL 0.06% and 0.08% PUMP (TOPICAL), to be added to the PDL as
    NONPREFERRED
  - o BENZACLIN (TOPICAL) and CLINDAGEL (TOPICAL) to be removed from the PDL.
- The committee discussed the Alzheimer's Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - ADLARITY (TRANSDERM) and MEMANTINE TABLET DOSE PACK (AG) (ORAL) to be added to the PDL as NONPREFERRED
  - RAZADYNE ER (ORAL) and RAZADYNE TABLET (ORAL) to be removed from the PDL.
- The committee discussed the Analgesics, Narcotics Long therapeutic class and recommended the following to the department by a unanimous vote:
  - CONZIP (ORAL), TRAMADOL ER (CONZIP) (ORAL), TRAMADOL ER (RYZOLT) (ORAL) and TRAMADOL ER (ULTRAM ER) (ORAL) to be added to the PDL as NONPREFERRED
  - KADIAN (ORAL) to be removed from the PDL.
- The committee discussed the Erythropoiesis Stimulating Proteins therapeutic class and recommended the following to the department by a unanimous vote:
  - JESDUVROQ (ORAL), MIRCERA (INJECTION) and RETACRIT (VIFOR) (INJECTION) to be added to the PDL as NONPREFERRED.
- The committee discussed the Growth Hormone therapeutic class and recommended the following to the department by a unanimous vote:

- GENOTROPIN CARTRIDGE (INJECTION) and GENOTROPIN DISP SYRIN (INJECTION) to be moved to the PDL as PREFERRED
- NGENLA (INJECTION), SKYTROFA CARTRIDGE (SUBCUTANEOUS) and SOGROYA (SUBCUTANEOUS) to be added to the PDL as NONPREFERRED.
- The committee discussed the Hypoglycemics, SGLT2 therapeutic class and recommended the following to the department by a unanimous vote:
  - DAPAGLIFLOZIN (ORAL), DAPAGLIFLOZIN/MEFORMIN ER (ORAL) and INPEFA (ORAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Ophthalmics, Anti-Inflammatories therapeutic class and recommended the following to the department by a unanimous vote:
  - XIPERE (SUPRACHOROIDAL INJECTION) to be added to the PDL as NONPREFERRED.
- The committee discussed the Ophthalmics, Glaucoma Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - DURYSTA IMPLANT (INTRACAMERAL), IDOSE TR IMPLANT (INTRACAMERAL), IYUZEH
     (OPHTHALMIC) and TAFLUPROST (OPHTHALMIC) to be added to the PDL as NONPREFERRED.
- The committee discussed the PAH Agents, Oral and Inhaled therapeutic class and recommended the following to the department by a unanimous vote:
  - LIQREV SUSPENSION (ORAL) and ORENITRAM TITRATION KIT (ORAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Sedative Hypnotics therapeutic class and recommended the following to the department by a unanimous vote:
  - TASIMELTEON (ORAL) and ZOLPIDEM CAPSULE (ORAL) to be added to the PDL as NONPREFERRED
  - Update the listing of ZOLPIDEM (ORAL) under preferred products to read ZOLPIDEM <u>TABLET</u> (ORAL).
- The committee discussed the Ulcerative Colitis Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - MESALAMINE (CANASA) (RECTAL) to be moved to the PDL as PREFERRED
  - CANASA (RECTAL) to be moved to the PDL as NONPREFERRED
  - o BUDESONIDE (RECTAL) to be added to the PDL as NONPREFERRED
  - ASACOL HD (ORAL), DELZICOL (ORAL) and MESALAMINE (LIALDA) (ORAL) to be removed from the PDL.

# **CONSENT AGENDA ITEMS:**

The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items be passed as presented with no changes.

# Adjournment

• The meeting was adjourned at approximately 1:06 p.m. Central Time.